M
Marc Piechaczyk
Researcher at University of Montpellier
Publications - 37
Citations - 1530
Marc Piechaczyk is an academic researcher from University of Montpellier. The author has contributed to research in topics: Transcription factor & SUMO protein. The author has an hindex of 22, co-authored 37 publications receiving 1203 citations. Previous affiliations of Marc Piechaczyk include Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
Nuclear localization of c-Fos, but not v-Fos proteins, is controlled by extracellular signals
Pierre Roux,Jean-Marie Blanchard,Anne Fernandez,Ned J.C. Lamb,Philippe Jeanteur,Marc Piechaczyk +5 more
TL;DR: It is reported that transport of the protein product of the c-fos proto-oncogene from the cytoplasm into the nucleus, where it operates as part of the AP-1 transcription complex, is not spontaneous but depends on the continuous stimulation of cells by serum factors.
Journal ArticleDOI
The AP-1 transcriptional complex: Local switch or remote command?
TL;DR: These studies strikingly indicate that AP-1 principally operates as a remote command binding to distal enhancers, placing chromatin architecture dynamics at the heart of its transcriptional actions.
Journal ArticleDOI
Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
TL;DR: Evidence is accumulating that monoclonal antibodies can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the period of immunotherapy, which may revolutionize antiviral mAb-based immunotherapies, with benefits for both patients and healthcare systems.
Journal ArticleDOI
Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL.
A E Sayan,A E Sayan,R Stanford,R Vickery,E Grigorenko,Jeannine Diesch,K Kulbicki,R. Edwards,Raj P. Pal,Peter Greaves,Isabelle Jariel-Encontre,Marc Piechaczyk,Marina Kriajevska,J K Mellon,Amardeep S. Dhillon,Eugene Tulchinsky +15 more
TL;DR: It is suggested that AXL may represent an attractive therapeutic target in cancers expressing high Fra-1 levels because of the fact that the gene coding for AXL tyrosine kinase is directly upregulated byFra-1 in bladder cancer and in other cell lines.
Journal ArticleDOI
The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs
Guillaume Bossis,Jean-Emmanuel Sarry,Chamseddine Kifagi,Marko Ristic,Estelle Saland,François Vergez,Tamara Salem,Héléna Boutzen,Hayeon Baik,Frédérique Brockly,Mireia Pelegrin,Tony Kaoma,Laurent Vallar,Christian Recher,Stéphane Manenti,Marc Piechaczyk +15 more
TL;DR: Targeting the ROS/SUMO axis might constitute a therapeutic strategy for AML patients resistant to conventional chemotherapies.